STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial

STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial

The unexpected result is good news for patients with acute myeloid leukemia Histopathology from patient with acute myeloid leukemia.CDC Nov. 17, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. It looks like I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy. On Tuesday, Sellas said the therapy, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia — an outcome that achieved the main goal of a Phase 3 clinical trial, the company said. In a column published in September, I predicted galinpepimut would fail to prolong survival in the Phase 3 study. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Original Source

Read the full article at Statnews →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.